TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02266641

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition counseling
Description: Pregnancy diet (include one-carbon nutrients)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition counseling
Description: Pregnancy diet (include one-carbon nutrients)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition counseling
Description: Pregnancy diet (include one-carbon nutrients)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin supplement
Study: NCT03483506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335 (C-14) intravenous solution
Description: Intravenous solution
Study: NCT02960048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilizing splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior repositioning splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
Study: NCT02029508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Epley maneuver
Description: For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semont maneuver
Description: Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Reverse Epley maneuver
Description: Like the modified Epley maneuver, but the direction was reverse.
Study: NCT03512002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued Current Care
Description: Continue their current clinical care.
Study: NCT04424355

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest MRI
Description: Patients referred by the primary care physician with suspected pneumonia
Study: NCT04507438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5-10 Mg Oral Tablet
Description: Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet administered daily for an 8 week period
Study: NCT03927248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: See description in Arms/Groups section
Study: NCT01122628

Intervention type: DEVICE
Intervention: ORIF with DVR-A locking plate
Description: Size, length of plate and number os screws decided by operating surgeon
Study: NCT02266641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin supplement
Study: NCT03683706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LTP in My Own Way Plus
Description: LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
Study: NCT03093714

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for FDL169
Study: NCT03184532

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: ultrasound examination of pyloric antrum

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: ultrasound examination of pyloric antrum
Study: NCT03146637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated CIK
Description: Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CIK
Description: Traditional CIK were infused for 3 days
Study: NCT01787279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously weekly, 48 weeks
Study: NCT02665091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education Program
Study: NCT02327377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavior Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Education
Study: NCT04505696

Intervention type: OTHER
Group type: OTHER
Intervention: Speech-Language Pathology Presentation
Description: 45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
Study: NCT02512068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin 25 mg
Description: Trelagliptin 25 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin 25 mg
Description: Trelagliptin 25 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Tablets
Study: NCT04360187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole Ointment
Description: Crisaborole ointment 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crisaborole Placebo Vehicle
Description: Placebo for crisaborole ointment
Study: NCT04069988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin program
Description: This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
Study: NCT00698841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
Study: NCT04046939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpramipexole
Description: dexpramipexole twice daily oral dosing for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpramipexole
Description: dexpramipexole twice daily oral dosing for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexpramipexole
Description: dexpramipexole twice daily oral dosing for up to 12 weeks
Study: NCT03799380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gatorade G2
Description: Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care nutritional support
Description: Standard of care nutritional support
Study: NCT02927132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
Study: NCT04046939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo twice daily oral dosing for up to 12 weeks
Study: NCT03561610

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sip feed
Description: normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
Study: NCT00942331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IV
Study: NCT03136874

Intervention type: OTHER
Intervention: Interview and questionaires
Description: * Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories.

Intervention type: OTHER
Intervention: Interview and questionaires
Description: * Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories.
Study: NCT03571659

Intervention type: PROCEDURE
Intervention: Laser

Intervention type: PROCEDURE
Intervention: Laser
Study: NCT04010916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Preoperatively Adductor Canal Block
Description: The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Preoperatively Tourniquet Adductor Canal Block
Description: The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Postoperatively Adductor Canal Block
Description: The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
Study: NCT01489618

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPS
Description: POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PnCJ PPS
Description: PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
Study: NCT03989531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: Drip infusion over 60 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drip infusion over 60 minutes
Study: NCT01513031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up
Description: Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
Study: NCT02523937

Intervention type: OTHER
Intervention: Soluble Fibrin
Description: Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.

Intervention type: OTHER
Intervention: Soluble Fibrin
Description: Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
Study: NCT01576302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Description: Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle relaxation
Description: Progressive passive muscle relaxation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle relaxation
Description: Progressive passive muscle relaxation
Study: NCT00622115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study: NCT01722682

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human pancreatic islet transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human pancreatic islet transplantation
Study: NCT03660215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediation
Description: support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
Study: NCT03561610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gumdrops
Description: normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
Study: NCT01915940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost ocular insert

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Description: Timolol 0.5% solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eye Drops
Description: Placebo topical eye drops

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Ocular Insert
Description: Ocular insert without any active drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ocular Insert
Description: Ocular insert without any active drug
Study: NCT03466541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Riskbruk
Description: The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
Study: NCT03323060

Intervention type: DEVICE
Intervention: Transanal endoscopic surgical procedure
Description: Resection of tumors or lesions
Study: NCT04412486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID Convalescent Plasma
Description: One unit of COVID Convalescent Plasma transfused on Day 0
Study: NCT02269956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 week feasibility study
Description: : At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
Study: NCT01647711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation followed by treatment with MTD
Description: Fixed 3+3 dose escalation; expansion of MTD cohort
Study: NCT04276935

Intervention type: OTHER
Intervention: Interview
Description: Participate in cognitive interview

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02310789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150mg administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-Adrenergic cocktail
Description: Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Nitrate 5%
Description: Administered subcutaneously using Macroduct sweat stimulator device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macroduct sweat stimulator
Study: NCT00506506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 1200 mg twice daily x 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03407612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Passive Motion
Description: CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.